193 related articles for article (PubMed ID: 31938588)
21. Prevalence of HER2 Positivity and Its Clinicopathological Correlation in Locally Advanced/Metastatic Gastric Cancer Patients in Malaysia.
Rajadurai P; Fatt HK; Ching FY
J Gastrointest Cancer; 2018 Jun; 49(2):150-157. PubMed ID: 28124769
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathologic characteristics of patients with stage III/IV (M(0)) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization.
Im SA; Kim JW; Kim JS; Kim MA; Jordan B; Pickl M; Han SW; Oh DY; Lee HJ; Kim TY; Kim WH; Yang HK; Bang YJ
Diagn Mol Pathol; 2011 Jun; 20(2):94-100. PubMed ID: 21532492
[TBL] [Abstract][Full Text] [Related]
23. The coexpression and prognostic significance of c-MET, fibroblast growth factor receptor 2, and human epidermal growth factor receptor 2 in resected gastric cancer: a retrospective study.
Jia YX; Li TF; Zhang DD; Fan ZM; Fan HJ; Yan J; Chen LJ; Tang H; Qin YR; Li XY
Onco Targets Ther; 2016; 9():5919-5929. PubMed ID: 27729801
[TBL] [Abstract][Full Text] [Related]
24. Clinical utility of HER2 assessed by immunohistochemistry in patients undergoing curative resection for gastric cancer.
Liu X; Xu P; Qiu H; Liu J; Chen S; Xu D; Li W; Zhan Y; Li Y; Chen Y; Zhou Z; Sun X
Onco Targets Ther; 2016; 9():949-58. PubMed ID: 27013889
[TBL] [Abstract][Full Text] [Related]
25. New protein kinase inhibitors in breast cancer: afatinib and neratinib.
Zhang X; Munster PN
Expert Opin Pharmacother; 2014 Jun; 15(9):1277-88. PubMed ID: 24787047
[TBL] [Abstract][Full Text] [Related]
26. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
[TBL] [Abstract][Full Text] [Related]
27. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.
Tevaarwerk AJ; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2332-48. PubMed ID: 20110044
[TBL] [Abstract][Full Text] [Related]
28. Current Targeted Therapies in HER2-Positive Gastric Adenocarcinoma.
Curea FG; Hebbar M; Ilie SM; Bacinschi XE; Trifanescu OG; Botnariuc I; Anghel RM
Cancer Biother Radiopharm; 2017 Dec; 32(10):351-363. PubMed ID: 29265917
[TBL] [Abstract][Full Text] [Related]
29. Towards the goal of personalized medicine in gastric cancer--time to move beyond HER2 inhibition. Part I: Targeting receptor tyrosine kinase gene amplification.
Lee J; Ou SH
Discov Med; 2013 Jun; 15(85):333-41. PubMed ID: 23819947
[TBL] [Abstract][Full Text] [Related]
30. Best Practices for Managing Patients with Unresectable Metastatic Gastric and Gastroesophageal Junction Cancer in Canada.
Snow S; Gabrielson D; Lim H; Tehfe M; Brezden-Masley C
Curr Oncol; 2024 Apr; 31(5):2552-2565. PubMed ID: 38785472
[TBL] [Abstract][Full Text] [Related]
31. HER2-targeted therapy: an emerging strategy in advanced colorectal cancer.
La Salvia A; Lopez-Gomez V; Garcia-Carbonero R
Expert Opin Investig Drugs; 2019 Jan; 28(1):29-38. PubMed ID: 30513002
[TBL] [Abstract][Full Text] [Related]
32. Targeted therapy in HER2-positive breast cancer.
Li SG; Li L
Biomed Rep; 2013 Jul; 1(4):499-505. PubMed ID: 24648975
[TBL] [Abstract][Full Text] [Related]
33. Survival benefit of anti-angiogenic agents in patients with previously treated advanced gastric or gastroesophageal junction cancer: a meta-analysis.
Kim JH; Kim HS; Kim BJ; Jang HJ
Oncotarget; 2017 Nov; 8(57):97565-97570. PubMed ID: 29228632
[TBL] [Abstract][Full Text] [Related]
34. Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study.
Meulendijks D; Beerepoot LV; Boot H; de Groot JW; Los M; Boers JE; Vanhoutvin SA; Polee MB; Beeker A; Portielje JE; de Jong RS; Goey SH; Kuiper M; Sikorska K; Beijnen JH; Tesselaar ME; Schellens JH; Cats A
Invest New Drugs; 2016 Feb; 34(1):119-28. PubMed ID: 26643663
[TBL] [Abstract][Full Text] [Related]
35. Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer.
Xuhong JC; Qi XW; Zhang Y; Jiang J
Am J Cancer Res; 2019; 9(10):2103-2119. PubMed ID: 31720077
[TBL] [Abstract][Full Text] [Related]
36. Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies.
Miller JA; Kotecha R; Ahluwalia MS; Mohammadi AM; Chao ST; Barnett GH; Murphy ES; Vogelbaum MA; Angelov L; Peereboom DM; Suh JH
Cancer; 2017 Jun; 123(12):2283-2293. PubMed ID: 28192598
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.
Phillips BE; Tubbs RR; Rice TW; Rybicki LA; Plesec T; Rodriguez CP; Videtic GM; Saxton JP; Ives DI; Adelstein DJ
Dis Esophagus; 2013 Apr; 26(3):299-304. PubMed ID: 22676551
[TBL] [Abstract][Full Text] [Related]
38. How will human epidermal growth factor receptor 2-neu data impact clinical management of gastric cancer?
Lorenzen S; Lordick F
Curr Opin Oncol; 2011 Jul; 23(4):396-402. PubMed ID: 21505336
[TBL] [Abstract][Full Text] [Related]
39. Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites.
Gumusay O; Benekli M; Ekinci O; Baykara M; Ozet A; Coskun U; Demirci U; Uner A; Dursun A; Atak EY; Buyukberber S
Jpn J Clin Oncol; 2015 May; 45(5):416-21. PubMed ID: 25732909
[TBL] [Abstract][Full Text] [Related]
40. Towards the goal of personalized medicine in gastric cancer--time to move beyond HER2 inhibition. Part II: Targeting gene mutations and gene amplifications and the angiogenesis pathway.
Lee J; Ou SH
Discov Med; 2013 Aug; 16(86):7-14. PubMed ID: 23911227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
